Total Funding
65
57
Total FundingVenture - Series Unknown raised
Growth Score
-2 pts
Heat Score
-4 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
106391
Revere Pharmaceuticals develops a drug discovery and development platform targeting Rac1 and its genomic variants.
- Robert Silverman: President and CEOPast Role: Vertex Pharmaceuticals, Patent Attorney
- Jedd Levine: Chief Medical Officer
About the Company
Revere Pharmaceuticals specializes in precision medicine to address unmet needs in cancer and other diseases by targeting Rac1 GTPase proteins that were once considered undruggable. It has developed an innovative drug discovery and development platform that drives its small molecule pipeline targeting Rac1 and its genomic variants. The platform
combines in silico modeling and proprietary assays with high-throughput screening capabilities to discover novel Rac1 and Cdc42 inhibitors. These enable the delivery of novel targeted therapeutics.
